283 related articles for article (PubMed ID: 23894047)
1. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature.
Hofmann SC; Leandro MJ; Morris SD; Isenberg DA
Lupus; 2013 Aug; 22(9):932-9. PubMed ID: 23894047
[TBL] [Abstract][Full Text] [Related]
2. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.
Vital EM; Wittmann M; Edward S; Md Yusof MY; MacIver H; Pease CT; Goodfield M; Emery P
Arthritis Rheumatol; 2015 Jun; 67(6):1586-91. PubMed ID: 25707733
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus.
Quelhas da Costa R; Aguirre-Alastuey ME; Isenberg DA; Saracino AM
JAMA Dermatol; 2018 Dec; 154(12):1432-1440. PubMed ID: 30383114
[TBL] [Abstract][Full Text] [Related]
4. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
[TBL] [Abstract][Full Text] [Related]
5. Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications.
Chlebus E; Wolska H; Blaszczyk M; Jablonska S
J Am Acad Dermatol; 1998 Mar; 38(3):405-12. PubMed ID: 9520021
[TBL] [Abstract][Full Text] [Related]
6. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.
Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Ann Rheum Dis; 2007 Sep; 66(9):1259-62. PubMed ID: 17412738
[TBL] [Abstract][Full Text] [Related]
7. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
[TBL] [Abstract][Full Text] [Related]
8. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.
Ezeonyeji AN; Isenberg DA
Rheumatology (Oxford); 2012 Mar; 51(3):476-81. PubMed ID: 22096015
[TBL] [Abstract][Full Text] [Related]
9. B cell biomarkers of rituximab responses in systemic lupus erythematosus.
Vital EM; Dass S; Buch MH; Henshaw K; Pease CT; Martin MF; Ponchel F; Rawstron AC; Emery P
Arthritis Rheum; 2011 Oct; 63(10):3038-47. PubMed ID: 21618204
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis.
Duxbury B; Combescure C; Chizzolini C
Lupus; 2013 Dec; 22(14):1489-503. PubMed ID: 24135078
[TBL] [Abstract][Full Text] [Related]
11. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.
Marks SD; Tullus K
Paediatr Drugs; 2007; 9(6):371-8. PubMed ID: 18052407
[TBL] [Abstract][Full Text] [Related]
12. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
Sfikakis PP; Boletis JN; Tsokos GC
Curr Opin Rheumatol; 2005 Sep; 17(5):550-7. PubMed ID: 16093832
[TBL] [Abstract][Full Text] [Related]
13. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients.
Vera-Recabarren MA; GarcĂa-Carrasco M; Ramos-Casals M; Herrero C
Br J Dermatol; 2010 Jan; 162(1):91-101. PubMed ID: 19785596
[TBL] [Abstract][Full Text] [Related]
15. B cell subset composition segments clinically and serologically distinct groups in chronic cutaneous lupus erythematosus.
Jenks SA; Wei C; Bugrovsky R; Hill A; Wang X; Rossi FM; Cashman K; Woodruff MC; Aspey LD; Lim SS; Bao G; Drenkard C; Sanz I
Ann Rheum Dis; 2021 Sep; 80(9):1190-1200. PubMed ID: 34083207
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y
J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation.
Turner-Stokes T; Lu TY; Ehrenstein MR; Giles I; Rahman A; Isenberg DA
Rheumatology (Oxford); 2011 Aug; 50(8):1401-8. PubMed ID: 21398661
[TBL] [Abstract][Full Text] [Related]
18. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B; Lindholm C; Pullerits R
Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus.
Carter LM; Isenberg DA; Ehrenstein MR
Arthritis Rheum; 2013 Oct; 65(10):2672-9. PubMed ID: 23839909
[TBL] [Abstract][Full Text] [Related]
20. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]